Experiences with

Lixisenatide

In this randomized controlled trial, lixisenatide reduced motor disability progression in Parkinson’s patients. 2. Individuals in the lixisenatide group experienced greater gastrointestinal side effects rates than individuals in the placebo group.

There are a couple of trials in progress as well such as exenatide and lixisenatide. I came across this supplement for GLP1. Is it similar to GLP1 agnostic? Did anyone try GLP1 supplements?https://ca.iherb.com/pr/pendulum-glp-1-probiotic-30-capsules/142029?

"Lixisenatide can cross the blood-brain barrier and is known to have neuroprotective properties in https://www.ccjm.org/page/mds-2023/glp1-r-agonist-parkinson#:~:text=Lixisenatide%20can%20cross%20the%20blood,%2C%20University%20Hospital%20Bordeaux%2C%20France.

The results reveal that after 12 months, those given lixisenatide showed essentially no progression of motor problems, while those given the placebo showed worsening symptoms, dropping around three points on the 132-point assessment scale – a modest difference, yet thought to be clinically meaningful

The progression of motor symptoms, like tremors and slowness of movement, was slowed in patients who took the treatment called lixisenatide, the research found. However, the research also found that nausea occurred in 46% of people receiving lixisenatide, and vomiting occurred in 13%.

Parkinson's treated and with symptoms less than 3 years. - If you enrolled, you received daily subcutaneous lixisenatide or a placebo. - The primary outcome was a change in the motor PD scale called the MDS UPDRS when on dopamine medication after one year.

[i]Sanofi pulled lixisenatide from the market at the beginning of 2023. The French drugmaker has said the discontinuation of the treatment was a business decision that was unrelated to its safety and efficacy.

- As a side note - it is interesting to see that GLP-1 agonists such as Lixisenatide and Exenatide, which increase insulin and reduce blood sugar, in recent human trials are showing promising results. It would seem that the whole metabolic energy system is linked to PD.

https://cureparkinsons.org.uk/2023/08/preliminary-phase-2-trial-results-of-lixisenatide/

https://scienceofparkinsons.com/2022/01/20/road2022/ Top 5 #Parkinsons clinical trial results we will be looking out for in 2022: * Phase II Lixisenatide study results * Phase II Liraglutide study results * Phase II PT320 study results (Lots of GLP-1R data) * Phase II UDCA "UP study" results * Phase

And we see this in the case of exenatide, where there are multiple ongoing Phase 2 trials in Parkinson’s for drugs that are very similar to exenatide (such as liraglutide and – both of which will be reporting results in 2022).

Not sure whether it's still on track after covid https://cureparkinsons.org.uk/2018/01/the-lixisenatide-trial/ https://clinicaltrials.gov/ct2/show/NCT03439943 And this one was in the USA, and was also originally due to report any day now https://cureparkinsons.org.uk/2020/07/the-liraglutide-trial/

Another GLP-1R agonist, Lixisenatide, may be more effective. There are various things to consider.